Page last updated: 2024-12-07
5,5'-dihydroxy-4,4'-bitryptamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
5,5'-dihydroxy-4,4'-bitryptamine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 130151 |
MeSH ID | M0206554 |
Synonyms (7)
Synonym |
---|
5,5'-dihydroxy-4,4'-bitryptamine |
3-(2-aminoethyl)-4-[3-(2-aminoethyl)-5-hydroxy-1h-indol-4-yl]-1h-indol-5-ol |
108535-01-9 |
(4,4'-bi-1h-indole)-5,5'-diol, 3,3'-bis(2-aminoethyl)- |
3,3'-bis(2-aminoethyl)-(4,4'-bi-1h-indole)-5,5'-diol |
DTXSID30148580 |
5,5/'-dihydroxy-4,4/'-bitryptamine |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Using PC12 cells as a model of neuronal cells, we show that the interaction between copper and serotonin is toxic to undifferentiated cells." | ( Copper induced oxidation of serotonin: analysis of products and toxicity. Coulson, EJ; Jones, CE; Taylor, PJ; Underwood, CK, 2007) | 0.34 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.75
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.75) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |